(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and not separately reported by Alliance News:
----------
Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - Four directors buy 23,387 American Depositary Shares in total at USD23.09 each, worth USD540,006, on Friday last week. Each ADS represents three ordinary shares. Chief Executive Officer Mark Rothera buys 6,063 ADSs, Chief Financial Officer Craig Tooman buys 8,662, and non-executive directors Steven Romano and Michael Davidson each buy 4,331.
----------
Duke Royalty Ltd - provider of alternative capital solutions to businesses in Europe - Three executives buy 635,639 shares at 35p each, worth GBP222,474, as part of Duke's GBP35 million share placing earlier this month. Chair Nigel Birrell and CEO Neil Johnson each buy 200,000 shares, while Executive Director Charlie Cannon Brookes buys 235,639 via Arlington Partners Fund. This is owned by Arlington Group Asset Management Ltd, in which he has a 50% interest. Separately, Duke Royalty says it has received EUR1.3 million from the exit of its investment in royalty partner Almondclose Ltd, which trades as Berkley Recruitment, a Cork-based resourcing and recruitment business. Says Berkeley investment delivered an internal rate of return of 16%, but it was subscale for Duke. It had come with Duke's acquisition of Capital Step in February 2019
----------
Chaarat Gold Holdings Ltd - mine in Armenia and development assets in Kyrgyz Republic - Chair Martin Andersson buys 585,000 shares via Labro Investments at average 30.32p and 30.54p, worth GBP177,680, on Thursday and Friday last week. He had bought 824,088 shares earlier in the week and 1.6 million shares the week before. Andersson now interested in 290.3 million shares, a 42.3% stake.
----------
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Chaarat Gold (CGH)
Duke Capital (DUKE)